美股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

百濟神州

294.55

+4.201.45%

盤後：294.550.00000.00%19:56 EDT

成交量：89.35萬

成交額：2.65億

市值：348.90億

市盈率：-79.54

高：300.00

開：297.50

低：293.51

收：290.35

資料載入中...

總覽公司新聞公告

美股異動 | 百濟神州(ONC.US)漲逾3% 一季度中國創新藥海外授權總額再創新高

百濟神州7月8日成交額為6492.56萬美元

又有2款創新藥擬納入優先審評，來自百濟神州、艾力斯

剛剛，原百濟神州大中華區CFO去向曝光！

一款國產抗癌藥，“少賣”570億

中国企业家杂志

百濟神州 DLL3/CD3 雙抗擬納入優先審評

Insight数据库

研報掘金丨天風證券：維持百濟神州“買入”評級，CDK4抑制劑展現出優異早期療效信號

百濟神州：CDK4抑制劑展現出優異早期療效信號後續將進入註冊臨牀研究階段

天风证券股份有...

百濟神州7月7日成交額為7745.23萬美元

中國醫藥行業：理性看待創新藥估值尋找優秀公司的買點

創新藥大牛市繼續，最受益也是中國最強的創新藥龍頭，高瓴資本重倉公司！

2025年醫藥市場格局重塑：創新藥企突圍與投資新機遇分析及數據解讀

剔除CXO，創新藥指數迎“提純”！

市值超越恆瑞醫藥，百濟神州憑什麼？

創新藥產業迎“黃金時代”：指數“提純”助力投資精準化

环球老虎财经app

【券商聚焦】招銀國際維持百濟神州(06160)美股買入評級指CDK4抑制劑顯示初步療效

正大天晴 HER2 雙抗首次啓動 III 期臨牀

Insight数据库

【百濟神州(06160.HK)根據2016期權及激勵計劃授出合共4.38萬股受限制股份單位】智通財經APP訊，百濟神州(

百濟神州(06160)根據2016期權及激勵計劃授出合共4.38萬股受限制股份單位

官宣了！單國洪加入百濟神州

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/ONC/news?page=3"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ONC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","market":"US","secType":"STK","nameCN":"百濟神州","latestPrice":294.55,"timestamp":1752868800000,"preClose":290.35,"halted":0,"volume":893526,"hourTrading":{"tag":"盘后","latestPrice":294.55,"preClose":294.55,"latestTime":"19:56 EDT","volume":2550,"amount":751110.08,"timestamp":1752883001543},"delay":0,"floatShares":75541600,"shares":118450658,"eps":-3.70325,"marketStatus":"已收盤","change":4.2,"latestTime":"07-18 16:00:00 EDT","open":297.5,"high":300,"low":293.51,"amount":264758392.69818002,"amplitude":0.022352,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.70325,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1753084800000},"marketStatusCode":5,"adr":0,"adrRate":13,"exchange":"NASDAQ","adjPreClose":290.35,"preHourTrading":{"tag":"盘前","latestPrice":299.25,"preClose":290.35,"latestTime":"09:29 EDT","volume":3281,"amount":982962.59878,"timestamp":1752845389593},"postHourTrading":{"tag":"盘后","latestPrice":294.55,"preClose":294.55,"latestTime":"19:56 EDT","volume":2550,"amount":751110.08,"timestamp":1752883001543},"volumeRatio":1.826344,"impliedVol":0.5068,"impliedVolPercentile":0.8519},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","floatShares":75541600,"roa":"-3.22%","roe":"-11.44%","lyrEps":-6.124009,"volumeRatio":1.826344,"shares":118450658,"dividePrice":0,"high":300,"amplitude":0.022352,"preClose":290.35,"low":293.51,"week52Low":148.81,"pbRate":"9.97","psRate":"8.36","week52High":300,"institutionHeld":0,"latestPrice":294.55,"eps":-3.70325,"divideRate":0,"volume":893526,"delay":0,"ttmEps":-3.70325,"open":297.5,"prevYearClose":184.71,"prevWeekClose":250.3,"prevMonthClose":242.07,"prevQuarterClose":242.07,"fiveDayClose":250.3,"twentyDayClose":252.78,"sixtyDayClose":252.77},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ONC\",pageSize:20,pageCount:3,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2550165585","title":"美股異動 | 百濟神州(ONC.US)漲逾3% 一季度中國創新藥海外授權總額再創新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2550165585","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550165585?lang=zh_tw&edition=fundamental","pubTime":"2025-07-09 21:59","pubTimestamp":1752069554,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周三，百济神州涨逾3%，报252.97美元。尤其，中国创新药License-out交易额激增，2024年海外授权首付款31.6亿美元，交易总额511亿美元，联邦制药、恒瑞医药等多笔大额授权刷新纪录，全球BD交易占比升至30%。2025年一季度，海外授权总额再创455亿美元纪录，并且已经接近2024年全年水平。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1315940.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06978","06160","BK1161","BK0239","BK1588","LU1969619763.USD","BK4526","BK1500","LU0588546209.SGD","LU0307460666.USD","688235","159992","BK4139","ONC","LU2328871848.SGD","BK1574","BK1583"],"gpt_icon":0},{"id":"2550504187","title":"百濟神州7月8日成交額為6492.56萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2550504187","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550504187?lang=zh_tw&edition=fundamental","pubTime":"2025-07-09 12:35","pubTimestamp":1752035720,"startTime":"0","endTime":"0","summary":"美东时间2025年7月8日，百济神州成交额为6492.56万美元，成交额较昨日减少16.17%，当日成交量为26.57万股。百济神州于2025年7月8日涨1.44%，报244.47美元，该股过去5个交易日涨0.99%，年初至今涨32.35%，过去60日涨18.49%。百济神州有自己的团队进行全球临床试验。截至2023年，百济神州的核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709123521a69e8b81&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709123521a69e8b81&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","BK4526","BK4139"],"gpt_icon":0},{"id":"2550276505","title":"又有2款創新藥擬納入優先審評，來自百濟神州、艾力斯","url":"https://stock-news.laohu8.com/highlight/detail?id=2550276505","media":"制药网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550276505?lang=zh_tw&edition=fundamental","pubTime":"2025-07-09 10:44","pubTimestamp":1752029048,"startTime":"0","endTime":"0","summary":"此次在中国拟纳入优先审评，将加速其在中国的上市进程，为中国患者带来福音。优先审评是 CDE 推出的加速药物获批上市的重要政策之一。此次百济神州的注射用塔拉妥单抗和艾力斯的甲磺酸伏美替尼片拟纳入优先审评，将有助于它们更快地进入市场，为癌症患者带来新的生机，推动我国肿瘤治疗领域的进一步发展。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709104646953b9c40&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709104646953b9c40&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4526","ONC","BK4139","06160","688578","688235"],"gpt_icon":0},{"id":"2550284503","title":"剛剛，原百濟神州大中華區CFO去向曝光！","url":"https://stock-news.laohu8.com/highlight/detail?id=2550284503","media":"CFO职业圈","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550284503?lang=zh_tw&edition=fundamental","pubTime":"2025-07-09 10:14","pubTimestamp":1752027296,"startTime":"0","endTime":"0","summary":"时隔4个月，他的新职位终于公布。详见《重磅！百济神州大中华区CFO离职》。加入亚盛医药之前，黄智先生担任百济神州大中华区和亚太区首席财务官、全球技术运营和全球商业财务负责人。在百济任职期间，他通过完整的全面预算管理及合理的全球布局资源优化，持续改善公司财务状况。据Veet Misra的领英资料，其工作经历详细如下：温馨提示关注并星标“CFO职业圈”，不错过每一篇新推送！","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709102329a43f2ee2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709102329a43f2ee2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06160","688235","BK0239","ONC"],"gpt_icon":0},{"id":"2550571442","title":"一款國產抗癌藥，“少賣”570億","url":"https://stock-news.laohu8.com/highlight/detail?id=2550571442","media":"中国企业家杂志","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550571442?lang=zh_tw&edition=fundamental","pubTime":"2025-07-09 08:00","pubTimestamp":1752019249,"startTime":"0","endTime":"0","summary":"6月2日，美国药企BMS与德国药企BNT宣布达成战略合作：双方将共同开发双抗药物BNT327，交易总金额高达90亿美元。在许多投资者看来，才一年多时间，这款药就溢价了80亿美元量级，普米斯“低价卖青苗”，被中间商赚了差价。最具代表性的企业是再鼎医药，一度通过密集引进14款药物，先后在美国、中国香港上市，市值曾突破千亿港元，股价超越腾讯，成为“最贵港股”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709080335a43ee493&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709080335a43ee493&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ZLAB","688331","01530","09688","ONC","06998","LEGN","600276","688321","BK4139","BK4505","01276","BK4585","02162","688235","02696","09995","09926","06160","BK4588"],"gpt_icon":0},{"id":"2549510933","title":"百濟神州 DLL3/CD3 雙抗擬納入優先審評","url":"https://stock-news.laohu8.com/highlight/detail?id=2549510933","media":"Insight数据库","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549510933?lang=zh_tw&edition=fundamental","pubTime":"2025-07-08 17:11","pubTimestamp":1751965869,"startTime":"0","endTime":"0","summary":"7 月 8 日，CDE 官网显示，百济神州申报的注射用塔拉妥单抗拟纳入优先审评，用于既往接受过至少 2 线治疗失败的广泛期小细胞肺癌成人患者的治疗。2025 年 5 月，百济神州宣布，与安进公司在中国联合开展的注射用塔拉妥单抗2 期临床研究 DeLLphi-307 已取得积极结果。基于 DeLLphi-301、DeLLphi-304 和 DeLLphi-307 研究所获得的积极结果，塔拉妥单抗有望为中国 SCLC 患者的二线、三线及后线治疗提供新的用药选择。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708171749a43db9a5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708171749a43db9a5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1969619763.USD","BK1500","BK1583","LU0307460666.USD","ONC","LU2328871848.SGD","BK1588","688235","BK1161","06160","LU0588546209.SGD"],"gpt_icon":0},{"id":"2549150765","title":"研報掘金丨天風證券：維持百濟神州“買入”評級，CDK4抑制劑展現出優異早期療效信號","url":"https://stock-news.laohu8.com/highlight/detail?id=2549150765","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549150765?lang=zh_tw&edition=fundamental","pubTime":"2025-07-08 16:00","pubTimestamp":1751961645,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4588","LU0307460666.USD","BK4203","BGB","BK4139","BK4526","ONC","BK0239","BK4561","BK1583","BK1588","688235","BK1161","LU0588546209.SGD","LU1969619763.USD","BK4190","BK4590","BK4225","BK4581","BK4585","BK4144","BK1500","HR","BC","BK0276","LU2328871848.SGD","601162","ET","GLP","06160"],"gpt_icon":0},{"id":"2549515128","title":"百濟神州：CDK4抑制劑展現出優異早期療效信號 後續將進入註冊臨牀研究階段","url":"https://stock-news.laohu8.com/highlight/detail?id=2549515128","media":"天风证券股份有...","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549515128?lang=zh_tw&edition=fundamental","pubTime":"2025-07-08 15:52","pubTimestamp":1751961140,"startTime":"0","endTime":"0","summary":"百济神州的CDK4 抑制剂BGB-43395 进度处于前列，有望成为全球第二款进入注册临床阶段的CDK4 抑制剂根据公司指引，BGB-43395 预计在未来的 6-12 个月内进入注册临床阶段。CDK4 抑制剂BGB-43395 在多个体内外药效评估中均展现出BIC 潜力BGB-43395 相较现有CDK4/6 抑制剂具有更高选择性。百济神州的BGB-43395 体内药代动力学数据符合预期，药效学活性强效。CDK4 抑制剂BGB-43395 具有更优抑制效力。所以对同靶点药物，百济神州的CDK4i 来说，3 个月的中位随访时间还未到中位起效时间。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708155225979e0bc2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708155225979e0bc2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06160","ONC","BK4526","BK4139"],"gpt_icon":0},{"id":"2549599755","title":"百濟神州7月7日成交額為7745.23萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2549599755","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549599755?lang=zh_tw&edition=fundamental","pubTime":"2025-07-08 12:29","pubTimestamp":1751948965,"startTime":"0","endTime":"0","summary":"美东时间2025年7月7日，百济神州成交额为7745.23万美元，成交额较昨日增加82.68%，当日成交量为32.09万股。百济神州于2025年7月7日跌1.83%，报240.99美元，该股过去5个交易日跌0.09%，年初至今涨30.47%，过去60日涨15.08%。百济神州有自己的团队进行全球临床试验。截至2023年，百济神州的核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708122927a43d2e69&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708122927a43d2e69&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4526","ONC"],"gpt_icon":0},{"id":"2549596030","title":"中國醫藥行業：理性看待創新藥估值 尋找優秀公司的買點","url":"https://stock-news.laohu8.com/highlight/detail?id=2549596030","media":"招银国际","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549596030?lang=zh_tw&edition=fundamental","pubTime":"2025-07-08 00:00","pubTimestamp":1751904000,"startTime":"0","endTime":"0","summary":"中国创新药的研发实力具备全球竞争力，创新药出海趋势将长期持续。创新药商保目录即将落地，对行业短期影响有限，长期将打开创新药支付空间。7 月1 日，医保局发布了医保目录和商保创新药目录调整工作方案，预计将于10-11 月公布结果。商保创新药目录采用价格协商的形式，由商保专家、医保部门与药企进行价格协商。但商业健康保险赔付率较低，2023 年商业健康保险赔付额仅为3,848 亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708120124a69c4119&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708120124a69c4119&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","06978","01801","02273","06699","BK1161","BK1219","02367","BK1574","01530"],"gpt_icon":0},{"id":"2549831645","title":"創新藥大牛市繼續，最受益也是中國最強的創新藥龍頭，高瓴資本重倉公司！","url":"https://stock-news.laohu8.com/highlight/detail?id=2549831645","media":"萝卜投研","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549831645?lang=zh_tw&edition=fundamental","pubTime":"2025-07-07 15:14","pubTimestamp":1751872499,"startTime":"0","endTime":"0","summary":"高瓴资本是百济神州的十大股东之一！经调整后，公司实现营业利润11.71亿元，净利润8.85亿元。公司总资产为421亿元，归属于上市公司股东的所有者权益为252亿元。继首季度盈利之后，6 月 26 日，百济神州举行了投资者研发日活动。HER2双抗泽尼达妥单抗于上个月在中国获批上市，直指HER2阳性实体瘤群体尚未满足的临床需求。其二为2025年创新药头部上市公司扭亏，2026年更多公司盈利。短期来看，2025年有望成为创新药企业收入集体放量的起点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250707151714a43b367b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250707151714a43b367b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0124384867.USD","BK4139","LU1861219969.SGD","ONC","LU0724618433.USD","BK4605","BK4512","ON","IE00BZ199S13.USD","LU1720051017.SGD","LU1854104046.USD","LU1548497426.USD","LU1861215975.USD","LU2360107325.USD","BK4526","BK4588","LU1854103824.USD","IE00BD6J9T35.USD","06160","LU1861220033.SGD","LU2298322129.HKD","LU2357305700.SGD","BK4585","LU0348723411.USD","BK4141","LU1861214812.USD","LU1978683503.SGD","LU1720051108.HKD"],"gpt_icon":0},{"id":"2549010653","title":"2025年醫藥市場格局重塑：創新藥企突圍與投資新機遇分析及數據解讀","url":"https://stock-news.laohu8.com/highlight/detail?id=2549010653","media":"报告大厅","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549010653?lang=zh_tw&edition=fundamental","pubTime":"2025-07-07 11:01","pubTimestamp":1751857263,"startTime":"0","endTime":"0","summary":"行业数据显示，全球BCL-2抑制剂市场将在2028年达到52亿美元规模，而乳腺癌靶向药物市场规模更将突破163亿美元，为创新药企提供结构性增长空间。2025年医药市场呈现出鲜明的结构性特征。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250707124736979c9a9a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250707124736979c9a9a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["159938","06160","688235","BK0188","BK0028","LU1997245094.SGD","LU2328871848.SGD","LU1328615791.USD","BK0183","BK0012","LU1655091616.SGD","LU1997245177.USD","159992","BK0196","LU0405327148.USD","LU1064131003.USD","ONC","600276","BK0239","LU1969619763.USD","LU2495084118.USD","LU1064130708.USD","LU1997244956.HKD","LU2488822045.USD","162414","BK0060","LU2148510915.USD","01276","LU0405327494.USD"],"gpt_icon":0},{"id":"2549718305","title":"剔除CXO，創新藥指數迎“提純”！","url":"https://stock-news.laohu8.com/highlight/detail?id=2549718305","media":"侃见财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549718305?lang=zh_tw&edition=fundamental","pubTime":"2025-07-07 10:44","pubTimestamp":1751856299,"startTime":"0","endTime":"0","summary":"在板块高歌猛进之际，6月30日，恒生指数公司宣布对恒生港股通创新药指数进行关键修订：明确剔除CXO企业，打造“纯度”100%的创新药指数。这次指数修订，将一次性剔除5家CXO企业、合计权重约20%，它们年初以来的涨幅均落后于指数整体表现。修订规则生效后，恒生港股通创新药指数将成为目前ETF跟踪的指数中首批“纯度”达100%的创新药指数。回测显示，指数经过“提纯”后表现将有全面的提升。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250707104842a699ffa3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250707104842a699ffa3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4526","CXO","ONC","BK4139","01801","06160","688235","600276"],"gpt_icon":0},{"id":"2549306385","title":"市值超越恆瑞醫藥，百濟神州憑什麼？","url":"https://stock-news.laohu8.com/highlight/detail?id=2549306385","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549306385?lang=zh_tw&edition=fundamental","pubTime":"2025-07-07 10:34","pubTimestamp":1751855640,"startTime":"0","endTime":"0","summary":"　　百济神州市值超越恒瑞医药背后，是中国创新药从“仿制跟随”到“全球引领”的一次历史性跨越。其中，国内创新药龙头药企百济神州首次上榜，排名第44位，一举超越了国内“医药一哥”恒瑞医药（46名），成为外界热议的话题。　　财报数据显示，2024年全年，百济神州实现总营收达272.14亿元，同比大增56.19%。2024年，恒瑞医药实现净利润63.37亿元，同比大增47.28%，创出历史新高。受此消息提振，百济神州股价持续上涨。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2025-07-07/doc-inferezn9899533.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1997245177.USD","BK1500","688235","600276","BK0028","BK1191","LU0405327148.USD","BK0012","LU1655091616.SGD","BK0060","LU2328871848.SGD","BK1583","BK0239","LU1328615791.USD","LU2495084118.USD","LU0588546209.SGD","BK0188","LU1064131003.USD","06160","BK4526","BK1161","BK0196","BK4139","LU0405327494.USD","01276","LU1997245094.SGD","BK0183","ONC","LU2148510915.USD","LU2488822045.USD","LU1969619763.USD","LU0307460666.USD","BK1588","LU1997244956.HKD","LU1064130708.USD"],"gpt_icon":0},{"id":"2548049393","title":"創新藥產業迎“黃金時代”：指數“提純”助力投資精準化","url":"https://stock-news.laohu8.com/highlight/detail?id=2548049393","media":"环球老虎财经app","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548049393?lang=zh_tw&edition=fundamental","pubTime":"2025-07-04 19:00","pubTimestamp":1751626802,"startTime":"0","endTime":"0","summary":"创新药指数修订“提纯”6月30日，恒生港股通创新药指数宣布修订编制方案，明确剔除CXO企业。也就是说，此次调整后，该指数成分股将全部由创新药研发企业构成，等修订生效后，该指数将成为ETF跟踪指数中首批“纯度”达100%的创新药指数。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704193508a436e2cd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704193508a436e2cd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02196","01093","LU1655091616.SGD","BK0060","BK0183","LU1328615791.USD","01530","BK0239","LU1064131003.USD","600276","688235","LU1997245094.SGD","SBHMY","LU0405327148.USD","BK0012","09688","ONC","BK0028","01177","LU1997244956.HKD","03692","01801","03933","LU2328871848.SGD","LU0405327494.USD","LU2495084118.USD","LU1969619763.USD","LU2488822045.USD","LU1064130708.USD","09926","600196","LU1997245177.USD","06160","BK0188","ZLAB","LU2148510915.USD","01276","159992","06990","BK0196"],"gpt_icon":0},{"id":"2548513853","title":"【券商聚焦】招銀國際維持百濟神州(06160)美股買入評級 指CDK4抑制劑顯示初步療效","url":"https://stock-news.laohu8.com/highlight/detail?id=2548513853","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548513853?lang=zh_tw&edition=fundamental","pubTime":"2025-07-04 13:44","pubTimestamp":1751607842,"startTime":"0","endTime":"0","summary":"金吾财讯 | 招银国际研报指，百济神州 CDK4抑制剂显示出良好的血液安全性，并降低了中性粒细胞减少发生率。百济的CDK4抑制剂BGB-43395展示出良好的血液学安全性，这得益于其更优的CDK4/CDK6选择性，从而减少了CDK6介导及非靶向的毒性。CDK4抑制剂的疗效数据仍在成熟中。泽布替尼在CLL一线及复发/难治患者中持续领跑新处方数，并已成为美国销售额最高的BTK抑制剂。公司计划于2026年为BGB-16673在CLL中提交加速批准申请。维持美股买入评级。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/MjZhZmU5OWE5M2M5YjFiNzE1NDI2Mjg5NzQxNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjZhZmU5OWE5M2M5YjFiNzE1NDI2Mjg5NzQxNQ==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1961652","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06160","688235","ONC"],"gpt_icon":0},{"id":"2548693336","title":"正大天晴 HER2 雙抗首次啓動 III 期臨牀","url":"https://stock-news.laohu8.com/highlight/detail?id=2548693336","media":"Insight数据库","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548693336?lang=zh_tw&edition=fundamental","pubTime":"2025-07-04 08:04","pubTimestamp":1751587443,"startTime":"0","endTime":"0","summary":"近日，正大天晴在ClinicalTrials.gov 官网上登记了一项TQB2930 用于HER2 阳性乳腺癌的 III 期临床试验。公开资料显示，这是该药启动的首个III 期。2025 年 ASCO 大会上公布的是该试验中队列 4 的数据，旨在评估 TQB2930 联合化疗对至少接受过两线治疗的 HER2 阳性乳腺癌患者的安全性和有效性。截至 2024 年 12 月 15 日，已有 55 例患者接受了 TQB2930 联合化疗治疗。除此之外，正大天晴TQB2930 和康宁杰瑞/石药集团Anbenitamab-KN-026 已进入 III 期临床。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704080948a4ce2d9d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704080948a4ce2d9d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","06160","ONC","688235"],"gpt_icon":0},{"id":"2548874793","title":"【百濟神州(06160.HK)根據2016期權及激勵計劃授出合共4.38萬股受限制股份單位】智通財經APP訊，百濟神州(","url":"https://stock-news.laohu8.com/highlight/detail?id=2548874793","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548874793?lang=zh_tw&edition=fundamental","pubTime":"2025-07-03 16:56","pubTimestamp":1751532966,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK0239","06160","LU2328871848.SGD","688235","BK1583","BK4526","LU0307460666.USD","BK1588","BK1161","BK4139","LU1969619763.USD","ONC","BK1500","LU0588546209.SGD"],"gpt_icon":0},{"id":"2548743878","title":"百濟神州(06160)根據2016期權及激勵計劃授出合共4.38萬股受限制股份單位","url":"https://stock-news.laohu8.com/highlight/detail?id=2548743878","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548743878?lang=zh_tw&edition=fundamental","pubTime":"2025-07-03 16:56","pubTimestamp":1751532966,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州(06160)发布公告，于2025年6月30日，董事会薪酬委员会根据2016期权及激励计划的条款授予216名承授人合共4.38万股美国存托股份受限制股份单位。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1313563.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06160","BK1161","BK0239","BK1588","LU1969619763.USD","BK4526","BK1500","LU0588546209.SGD","LU0307460666.USD","688235","BK4139","ONC","LU2328871848.SGD","BK1583"],"gpt_icon":0},{"id":"2548878854","title":"官宣了！單國洪加入百濟神州","url":"https://stock-news.laohu8.com/highlight/detail?id=2548878854","media":"谈思生物","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548878854?lang=zh_tw&edition=fundamental","pubTime":"2025-07-03 15:00","pubTimestamp":1751526058,"startTime":"0","endTime":"0","summary":"武田中国前总裁单国洪8月加盟百济神州，执掌大中华区及中亚南亚业务，加速跨国药企新兴市场布局。多家自媒体消息显示，原武田制药全球高级副总裁、中国区总裁单国洪将于2025年8月18日正式加入百济神州，担任大中华区及中亚、南亚区域总经理，届时将向吴晓滨博士汇报工作。6月17日上午，武田全球生物制药及国际市场业务集团总裁施睿娜向内部员工宣布了单国洪的人事变动：其决定离开武田，寻求外部发展机会。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250703150859a72c1985&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250703150859a72c1985&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4526","06160","688235","ONC"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":3,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ONC\",params:#limit:5,,,undefined,":[{"date":"2025-08-30","symbol":"ONC","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756540800000,"name":null,"time":"盤前","dateTimestamp":1756526400000,"actualEps":null},{"market":"US","date":"2025-05-07","symbol":"ONC","fiscalQuarterEnding":"2025/03","expectedEps":-0.71,"name":null,"time":"盤前","type":"earning","dateTimestamp":1746590400000,"reportTimeType":"pre","actualEps":1.22},{"market":"US","date":"2025-02-27","symbol":"ONC","fiscalQuarterEnding":"2024/12","expectedEps":-0.88,"name":null,"time":"盤前","type":"earning","dateTimestamp":1740632400000,"reportTimeType":"pre","actualEps":-1.43},{"market":"US","date":"2024-11-12","symbol":"ONC","fiscalQuarterEnding":"2024/09","expectedEps":-0.88,"name":null,"time":"盤前","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-1.15},{"market":"US","date":"2024-08-07","symbol":"ONC","fiscalQuarterEnding":"2024/06","expectedEps":-2.1,"name":null,"time":"盤前","type":"earning","dateTimestamp":1723003200000,"reportTimeType":"pre","actualEps":-1.15}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ONC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ONC\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3182,"buy":0.6364,"hold":0.0455,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6364,"analysts":22,"updateTime":1748318400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ONC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ONC","date":"2025-07-17","current":-84.275105,"percent":0.021127,"low":-89.808695,"twenty":-47.010053,"median":-39.274234,"eighty":-23.175318,"high":-19.234246,"avg":-40.083783,"sd":18.230961,"marketCap":33066685687},"quantilePoints":[{"date":"2024-05-31","current":-19.860847,"twenty":-20.46703,"median":-20.284421,"eighty":-20.042184,"marketCap":15579384952},{"date":"2024-06-07","current":-20.864085,"twenty":-20.930269,"median":-20.558927,"eighty":-20.042184,"marketCap":16366351618},{"date":"2024-06-14","current":-21.694058,"twenty":-21.409839,"median":-20.844737,"eighty":-20.30869,"marketCap":17017405001},{"date":"2024-06-21","current":-20.966373,"twenty":-21.331475,"median":-20.876952,"eighty":-20.46703,"marketCap":16446589390},{"date":"2024-06-28","current":-19.234246,"twenty":-21.331475,"median":-20.825389,"eighty":-19.981739,"marketCap":15087861974},{"date":"2024-07-05","current":-19.83401,"twenty":-21.208618,"median":-20.693442,"eighty":-19.760805,"marketCap":15558333278},{"date":"2024-07-12","current":-20.525989,"twenty":-21.135228,"median":-20.465877,"eighty":-19.641074,"marketCap":16101139655},{"date":"2024-07-19","current":-20.872652,"twenty":-21.016911,"median":-20.525989,"eighty":-19.707798,"marketCap":16373071895},{"date":"2024-07-26","current":-21.924783,"twenty":-21.374239,"median":-20.660298,"eighty":-19.760805,"marketCap":17198391533},{"date":"2024-08-02","current":-22.081827,"twenty":-21.704901,"median":-20.777003,"eighty":-19.839377,"marketCap":17321581561},{"date":"2024-08-09","current":-37.033118,"twenty":-22.009534,"median":-20.868368,"eighty":-19.874904,"marketCap":19394058972},{"date":"2024-08-16","current":-39.443432,"twenty":-22.36867,"median":-20.966373,"eighty":-19.937065,"marketCap":20656328240},{"date":"2024-08-23","current":-39.274234,"twenty":-33.284244,"median":-21.171036,"eighty":-20.00126,"marketCap":20567720015},{"date":"2024-08-30","current":-38.860864,"twenty":-37.912544,"median":-21.248991,"eighty":-20.190606,"marketCap":20351240040},{"date":"2024-09-06","current":-38.812817,"twenty":-38.506257,"median":-21.456019,"eighty":-20.300725,"marketCap":20326078245},{"date":"2024-09-13","current":-40.29759,"twenty":-38.865563,"median":-21.710093,"eighty":-20.355918,"marketCap":21103646159},{"date":"2024-09-20","current":-41.008162,"twenty":-39.353261,"median":-21.954664,"eighty":-20.405766,"marketCap":21475769498},{"date":"2024-09-27","current":-44.343793,"twenty":-39.883427,"median":-22.072098,"eighty":-20.507104,"marketCap":23222622772},{"date":"2024-10-04","current":-49.961787,"twenty":-40.117185,"median":-22.410559,"eighty":-20.525989,"marketCap":26164738255},{"date":"2024-10-11","current":-47.875901,"twenty":-40.317892,"median":-22.855632,"eighty":-20.558927,"marketCap":25072369873},{"date":"2024-10-18","current":-44.402313,"twenty":-41.008162,"median":-37.033118,"eighty":-20.627155,"marketCap":23253269086},{"date":"2024-10-25","current":-43.1532,"twenty":-43.068033,"median":-37.882149,"eighty":-20.693442,"marketCap":22599114920},{"date":"2024-11-01","current":-41.429716,"twenty":-43.148001,"median":-38.271158,"eighty":-20.724275,"marketCap":21696535276},{"date":"2024-11-08","current":-41.685343,"twenty":-43.068033,"median":-38.746669,"eighty":-20.777003,"marketCap":21830405481},{"date":"2024-11-15","current":-24.188369,"twenty":-42.835701,"median":-38.506257,"eighty":-20.825389,"marketCap":20104967290},{"date":"2024-11-22","current":-24.46985,"twenty":-42.494274,"median":-38.062423,"eighty":-20.864085,"marketCap":20240962418},{"date":"2024-11-29","current":-27.613239,"twenty":-42.262623,"median":-37.45966,"eighty":-20.870939,"marketCap":22851200825},{"date":"2024-12-06","current":-26.519964,"twenty":-42.078114,"median":-35.811244,"eighty":-20.886386,"marketCap":21862847938},{"date":"2024-12-13","current":-23.158686,"twenty":-41.984053,"median":-26.690447,"eighty":-20.951062,"marketCap":19077141333},{"date":"2024-12-20","current":-22.876382,"twenty":-41.961072,"median":-26.519964,"eighty":-21.016911,"marketCap":18791641889},{"date":"2024-12-27","current":-23.581122,"twenty":-41.848457,"median":-25.970587,"eighty":-21.108807,"marketCap":19365505627},{"date":"2025-01-03","current":-23.522344,"twenty":-41.738903,"median":-25.015322,"eighty":-21.169159,"marketCap":19262068568},{"date":"2025-01-10","current":-23.039426,"twenty":-41.667895,"median":-24.95255,"eighty":-21.188412,"marketCap":18831625271},{"date":"2025-01-17","current":-27.361812,"twenty":-41.564427,"median":-24.990614,"eighty":-21.226086,"marketCap":22387798297},{"date":"2025-01-24","current":-28.60727,"twenty":-41.429716,"median":-25.817461,"eighty":-21.248991,"marketCap":23666613889},{"date":"2025-01-31","current":-29.006926,"twenty":-41.129457,"median":-26.292693,"eighty":-21.405551,"marketCap":23976726670},{"date":"2025-02-07","current":-29.003485,"twenty":-41.095232,"median":-26.532547,"eighty":-21.456019,"marketCap":23849552911},{"date":"2025-02-14","current":-29.812673,"twenty":-41.008162,"median":-26.754345,"eighty":-21.694058,"marketCap":24634934161},{"date":"2025-02-21","current":-32.964646,"twenty":-40.974605,"median":-27.361812,"eighty":-21.704901,"marketCap":27250381776},{"date":"2025-02-28","current":-45.085214,"twenty":-41.025576,"median":-28.423545,"eighty":-21.711581,"marketCap":29070314911},{"date":"2025-03-07","current":-41.087466,"twenty":-41.189509,"median":-28.729221,"eighty":-21.882341,"marketCap":26492622821},{"date":"2025-03-14","current":-43.209977,"twenty":-41.608729,"median":-28.790129,"eighty":-21.948688,"marketCap":27861188167},{"date":"2025-03-21","current":-42.024306,"twenty":-41.961072,"median":-29.003485,"eighty":-22.009534,"marketCap":27096684166},{"date":"2025-03-28","current":-44.59433,"twenty":-42.028738,"median":-29.052749,"eighty":-22.054545,"marketCap":28753799426},{"date":"2025-04-04","current":-39.846019,"twenty":-42.270172,"median":-29.231496,"eighty":-22.077935,"marketCap":25692155286},{"date":"2025-04-11","current":-38.484462,"twenty":-42.209323,"median":-29.379987,"eighty":-22.177258,"marketCap":24814242135},{"date":"2025-04-17","current":-38.603,"twenty":-42.109763,"median":-29.75631,"eighty":-22.326782,"marketCap":24890673891},{"date":"2025-04-25","current":-40.929408,"twenty":-42.213935,"median":-30.85745,"eighty":-22.4234,"marketCap":26390709308},{"date":"2025-05-02","current":-42.799955,"twenty":-42.322726,"median":-33.161649,"eighty":-22.493794,"marketCap":27596811853},{"date":"2025-05-09","current":-63.824658,"twenty":-42.611855,"median":-33.528671,"eighty":-22.601969,"marketCap":25042625921},{"date":"2025-05-16","current":-62.94985,"twenty":-42.804476,"median":-34.892623,"eighty":-22.71748,"marketCap":24699380815},{"date":"2025-05-23","current":-72.041871,"twenty":-43.150081,"median":-36.84391,"eighty":-22.787779,"marketCap":28266780880},{"date":"2025-05-30","current":-74.527648,"twenty":-43.429182,"median":-37.087829,"eighty":-22.808465,"marketCap":29242115209},{"date":"2025-06-06","current":-77.688492,"twenty":-43.794804,"median":-38.030583,"eighty":-22.84042,"marketCap":30482322820},{"date":"2025-06-13","current":-89.808695,"twenty":-44.177303,"median":-38.271158,"eighty":-22.941372,"marketCap":35237878321},{"date":"2025-06-20","current":-76.439732,"twenty":-44.40516,"median":-38.484462,"eighty":-23.038971,"marketCap":29992352055},{"date":"2025-06-27","current":-76.95683,"twenty":-44.800569,"median":-38.641761,"eighty":-23.063278,"marketCap":30195243589},{"date":"2025-07-03","current":-74.11053,"twenty":-45.138397,"median":-38.836841,"eighty":-23.158686,"marketCap":29078452032},{"date":"2025-07-11","current":-76.495446,"twenty":-45.905367,"median":-39.006759,"eighty":-23.171606,"marketCap":30014212230},{"date":"2025-07-17","current":-84.275105,"twenty":-47.010053,"median":-39.274234,"eighty":-23.175318,"marketCap":33066685687}],"updateTime":1752866648312}}}